Results: Total doses from 3 fractions for the D5 v median 48.7Gy (range 31.4 -76.6Gy), D2 v median 64.0Gy (range: 43.2 -112Gy) and RV median dose 16.3Gy (range: 11.6 -25.3Gy) The RV point exhibited a weak correlation with D2 v (r=0.56; p=0.0001) and D5 v (r = 0.55; p=0.0001) respectively. A moderate correlation was observed between the HRCTV volume and the D2 v (r = 0.69; p=0.0001), the HRCTV volume and D5 v (r = 0.73; p=0.0001) and a weak correlation with the HRCTV volume and the RV Point (r= 0.57; p= 0.0001). The slope correlated with D2 v (r= -0.96; p=0.0001) and D5 v (r=-0.87; p=0.0001) and a weak correlation with the RV point (r=-0.52; p= 0.0002). No correlation was found between the HRCTV D90 and the D2v (r= -0.20; p= 0.1826), the D5v (r= -0.24; p=0.1082), or the RV Point (r=0.02; p=0.8431).
Material and Methods:
We investigated 28 patients treated with HDR-ISBT at National Hospital Organization Osaka National Hospital between May 2003 and December 2010. All patients received radical surgery and 7 patients also received post-operative radiotherapy as previous treatments. Histologic finding was adenocarcinoma and squamous cell carcinoma for 11 and 17 patients. In 11 adenocarcinoma patients, 6 patients had endometrioid adenocarcinoma and the other 5 patients had mucinous adenocarcinoma. The median tumor size was 23 mm (range; 5-79 mm). In 21 patients who had no irradiation history, 9 patients were treated with HDR-ISBT alone and the other 12 patients were treated with HDR-ISBT plus external beam radiotherapy (EBRT). Forty-eight to 54 Gy in 8 to 9 fractions were delivered as monotherapy and 30 to 33 Gy in 5 to 6 fractions as combination of EBRT. In 7 patients who had irradiation history, slight lower doses (42 to 48 Gy in 7 to 8 fractions) were selected. We implanted 7-15 (median, 12) applicators under transrectal ultrasonography guidance. We used freehand implantation with ambulatory technique for later 25 patients. Magnetic resonance imaging (MRI)-assisted imagebased treatment planning was performed for later 17 patients. Clinical target volumes (CTV) were the gloss tumor volume with or without 10 mm of vaginal margin for patients with or without non-irradiation history.
Results:
The median follow-up time was 43 months (range; 4-115 months). The median D90(CTV)s were 120%prescribed dose (PD), 122%PD and 118%PD for patients who had endometrioid adenocarcinoma, mucinous adenocarcinoma and squamous cell carcinoma. The 3-year local control and overall survival rates were 72% and 73% for adenocarcinoma. The 3-year local control and overall survival rates were 88% and 77% for squamous cell carcinoma. No significant difference was observed. The 3-year local control rates were both 67% for endometrioid adenocarcinoma and mucinous adenocarcinoma. Grade 3-4 late complications occurred by HDR-ISBT in 5 patients (18%).
Conclusion:
Our treatment result of image-based HDR-ISBT showed that slight inferior result was observed in cervical adenocarcinoma although there was no significant difference.
EP-1970
Dose to organs at risk on CT versus MRI based brachytherapy for cervix cancer K. Akbarov Recently 3D planning for brachytherapy has been used which could be done both by CT and MRI imaging based. We compared the high risk clinical target volumes contoured on CT and MRI and dose distribution in the target volumes and organs at risk.
Material and Methods:
Twenty three patients with IIA-IIIB stage cervical cancer were planned for HDR brachytherapy with ring-tandem applicators. Treatment consisted of four 7 Gy fractions by two insertion procedures. On MRI and CT sets we contoured HR CTV and organs at risk on 42 plans: for 19 patients two plans and for four patients only one. Medical physicists received task to make planning on CT and MRI images independently at the same day before irradiation. The mean HR CTV volume, dose received by at least 90% of the volume (D90) and the dose to 2 cc for the organs at risk were evaluated.
Results:
The mean volume of HR CTV was 77.5 cc on CT based contours and 60.3 cc on MRI imaging. This difference in HR CTV volume reflected on the dose to organs at riskphysicists have to increase it to achieve prescribed dose in target volume. Thus, while assessing mean D2cc for rectum, bladder and sigmoid we find out that it was lower in case of MRI based planning compare to CT based planning -66.2 Gy and 70.3 Gy, 85.1 Gy and 89.6 Gy, 62.3 Gy and 66.7 Gy respectively. Mean D90 also was significantly higher in MRI compared to CT imaging plans -94,2% versus 79,4% of prescribed dose.
Conclusion:
In spite that superiority of MRI compared to CT imaging based contouring and planning for HR CTV dose distribution has been already showed in previous studies we found that it also allows indirectly significantly decrease the dose to organs at risk during HDR brachytherapy for cervical cancer.
EP-1971
Result of IGBT for cervical cancer using ring applicator with 'Siriraj Ring Cap' extension P. Dankulchai Results: For high risk clinical target volume (HR CTV) the median was volume 37.4 cm3 (range; 15.3-76.1 cm3) and the median of D90 was 85.3Gy (range; 76.4-90.5Gy). The median of D2cc for bladder, rectum, sigmoid, and bowel loop were 84Gy (range; 68.3-89.7Gy), 66.1Gy (range; 56.8-76.3Gy), 65.6 (range; 49-77.1Gy), and 61.9Gy (range; 45.8-78.1Gy), respectively. 81.2% (95 of 117 plans) were performed using VariSourceTM ring applicator with 'Siriraj Ring Cap' extension, while mean of coverage of the HR CTV was 89.2% (range; 57-99%). 18.8% (22 of 117 plans) were applied using tandem with ovoids, and mean of coverage of the HR CTV was 79.9% (range; 53-96%). Median follow up was 10.6 months. The actuarial 1 year loco-regional recurrence free survival rate was 90.5% (95% confidence interval (CI); 67-98%), progression free survival rate was 85.7% (95% CI; 62-95%), and overall survival rate was 95.4% (95% CI; 71-99%). One patient had a grade 2 late rectal complication. No grade 3-5 late complications have been recorded so far.
Conclusion:
IGBT with or without hybrid technique using VariSourceTM titanium ring applicator with 'Siriraj Ring Cap' extension is applicable for locally advanced cervical cancer resulting in an excellent local control rate and limited morbidity. Purpose or Objective: The effectiveness of radiation therapy in the management of cervical cancer of all stages is well established. Radiation therapy usually consists of a combination of external beam therapy and brachytherapy. Further exploration of new approaches and methodologies is a promising direction of development. Given the radiobiological aspects and an important economic factor, i.e. reduction of hospital stay. The aim of this study was to estimate the effectiveness of the treatment of cervical cancer patients using adaptive image-guided brachytherapy (IGBT) during split course.
EP-1972 Application of adaptive brachytherapy in the treatment of cervical cancer in accelerated mode

Material and Methods:
In the period from May 2014, 38 patients with primary cervical cancer were treated with combined radiotherapy using the new split-adaptive methodology for IGBT. We used conformal radiation techniques: BOX method, IMRT or RapidArc. Total dose on the pelvic area and regional metastases was 50 Gy. Further HDR IGBT brachytherapy was followed with dosimetry planning MRI -images. The treatment was on 1st and 2nd , 8th and 9th days, ring tandem applicators implantation under general anesthesia. Between the fractions 1 and 2 and 3 and 4, the patients were with applicator under the supervision of medical staff during the day. Monitoring planning was conducted according to MRI-studies; as a result treatment plan was composed for every 2 fractions. The position of the applicator in relation to the tumor and critical organs during the day doesn't change provided that the methodology is being correctly observed. Dose plans were optimized for maximal tumor dose (D90) and coverage (V100 and V80). The dose parameters in the target volume are the following: D 90 = 7.3 (5.9-9.1) Gy, V 100 = 91.5 (79.2-99.1) %, V 80 = 97.8 (90.5 -100). Of the patients it was T2bN0M0 -7 patients, T3bN0M0 -5, T2b-3bN1M0 -18, T2b-3bN1M1 -8.
Results: in the results the values of dose rates (D 2 cc / D 0,1 cc) to organs of risk (bladder, rectum and sigmoid) are the following: 3.7 (1.7-7) / 4.8 (2.2 -9.4) Gy; 3.1 (1.2-6) / 4.2 (1.4 -8.3) and 3.9 (2.2-5.7) / 5.5 (3.5 -7.6) Gy. During follow-up time for 12 months no any acute or late toxicity of grade 2 were observed and not observed any difference in comparison with the fractionation scheme used previously. No one local recurrence were observed, regional recurrence in 2 (2 and 7 months), distant metastasis in 1 (12 months). The patients have undergone the treatment satisfactorily. The number of surgical implantations decreases from 4 to 2. According to preliminary data, local radiation reactions are not multiple.
